September 22, 2023 02:13 PM EDT
Pharma
FDA+

Boehringer In­gel­heim, Eli Lil­ly clinch new FDA ap­proval for block­buster Jar­diance to treat chron­ic kid­ney dis­ease

Lia DeGroot

Boehringer In­gel­heim and Eli Lil­ly nabbed a sec­ond FDA ap­proval for block­buster Jar­diance (em­pagliflozin), this time to treat adults with chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

A mixed year for deals and dol­lars left biotech ex­ecs hun­gry for a bet­ter 2025

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

A service from the Financial Times